Pharmaceuticals News and Research

RSS

Mylan launches Famciclovir Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Famciclovir Tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir® Tablets, a treatment for herpes.

20 Apr 2011

bluebird bio announces receipt of additional $30 million in financing

bluebird bio, an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced that the company has secured an additional $30 million in financing.

20 Apr 2011

Adeona, TG United enter commercial-scale manufacturing agreement for reaZin

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement with TG United, Inc. of Brooksville, Florida, to provide commercial-scale manufacturing capabilities for reaZin. Adeona is developing reaZin, its product candidate for the dietary management of Alzheimer's disease and mild cognitive impairment, as a prescription medical food.

20 Apr 2011

Forest acquires worldwide rights to novel antiarrhythmic agent azimilide

Forest Laboratories, Inc. today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.

20 Apr 2011

Sartorius first-quarter sales revenue increases 14.4% to 172.1 million euros

Sartorius started off fiscal 2011 with double-digit growth rates in order intake, sales revenue and profit. "We are currently seeing dynamic growth fueled by both divisions and all business regions. Compared with the year-earlier quarter, though also slightly below average, we have achieved highly encouraging rates of increase in revenue and profit," said CEO Dr. Joachim Kreuzburg.

From Sartorius 20 Apr 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

ADVANCELL, an emerging Spanish biopharmaceutical company, has initiated a phase IIb clinical study of the Company's ATH008, for the treatment of the palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome, a painful side-effect of certain chemotherapies such as capecitabine and fluoropyrimidines.

20 Apr 2011

Scientists detect several biomarkers to screen active drugs for Batten disease

Goethe University and Harvard Medical School start screening for active ingredients for the treatment of Batten disease

20 Apr 2011

Covidien supports FDA’s REMS for important class of pain medications

Covidien (NYSE: COV), a leading global provider of healthcare products, supports the U.S. Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) for an important class of pain medications.

20 Apr 2011

Combination therapy restores skilled use of limb in rodent model

After the acute treatment window closes, the only effective treatment for stroke is physical/occupational therapy. Now scientists from Children's Hospital Boston report a two-pronged molecular therapy that leads to significant recovery of skilled motor function in a rat model of stroke.

20 Apr 2011

Alnylam, Precision NanoSystems enter collaboration for discovery of novel small lipid nanoparticles

Precision NanoSystems, Inc. and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the two companies have formed an exclusive collaboration focused on the discovery and development of novel lipid nanoparticles, known as small lipid nanoparticles ("sLNPs"), using microfluidics technology.

From Precision NanoSystems Inc. 20 Apr 2011

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Biothera announced today that its second Phase II non-small cell lung cancer trial, evaluating Imprime PGG® in combination with bevacizumab (Avastin®) and two chemotherapeutic agents, has achieved its stage 1 endpoint and has begun enrolling patients for stage 2 of the study.

20 Apr 2011

Adamis acquires cancer vaccine technology from UCSD

Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.

20 Apr 2011

Sagent prices initial public offering at $16.00 per share

Sagent Pharmaceuticals announced the upsizing and pricing of its initial public offering. The size of the offering has been increased from the previously announced 5,000,000 shares of common stock to 5,750,000 shares of common stock at a price to the public of $16.00 per share. The shares are scheduled to begin trading on The NASDAQ Global Market on April 20, 2011 under the ticker symbol "SGNT."

20 Apr 2011

SERI selects AB SCIEX TripleTOF 5600 system to test chronic eye inflammations

AB SCIEX, a global leader in life science analytical technologies, today announced that the Singapore Eye Research Institute, an internationally known eye research center, will advance biomarker candidates it identified for chronic inflammatory eye conditions into large-scale clinical trials for validation with the AB SCIEX TripleTOF™ 5600 System.

20 Apr 2011

Ampio raises $12.732 million through private placement of common stock

Ampio Pharmaceuticals, Inc. announced today the successful completion of a private placement from which Ampio received gross proceeds of $12.732 million.

20 Apr 2011

Positive results from first human masitinib phase 2 study in Alzheimer's disease published in peer-reviewed journal

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of results from the first human phase 2 study of masitinib carried-out in the treatment of Alzheimer's disease.

20 Apr 2011

TCI forecasts cancer vaccine market to approach $3 billion in 2015

Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on cancer trends and development has identified cancer vaccines as a viable treatment option for a variety of cancers that currently have ineffective treatments. The potential of the cancer vaccine market is forecast to approach $3 billion in 2015.

20 Apr 2011

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.

20 Apr 2011

Axios' bio-based trackable pallet and software technology achieves FDA compliance

Axios Mobile Assets Corporation today announced it has achieved FDA compliance for its proprietary bio-based trackable pallet and software technology. The solutions meet FDA standards for CFR 21 part 11 compliance based on the pallet's material composition, in accordance to the U.S. Federal Code of Regulation.

20 Apr 2011